TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti–PD-1/anti–CTLA-4 immunotherapyHeng-Jia Liu, Elizabeth P. Henske, Maria C. Speranza et al.|JCI Insight|2018Cited by 74
Abstract 1686: TSC2 enhances antitumor immunity and potentiates PD-1 and CTLA-4 blockadeHeng-Jia Liu, Elizabeth P. Henske, Patrick H. Lizotte et al.|Cancer Research|2018Cited by 2